Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 4/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154861 | 0.82 | KDM4E (0.47) | HINT1HPGDSTING1 | |
| SCHEMBL20154870 | 0.81 | HINT1 (0.52) | HINT1NT5ESTING1GSK3ARPS6KA3 | |
| SCHEMBL19590333 | 0.76 | HINT1 (0.47) | HINT1NT5EHPGDSTING1GSK3A | |
| SCHEMBL26808492 | 0.75 | HINT1 (0.51) | HINT1NT5EHPGDSTING1GSK3A | |
| SCHEMBL25807955 | 0.75 | HINT1 (0.51) | HINT1NT5EHPGDSTING1GSK3A | |
| SCHEMBL27216242 | 0.75 | HINT1 (0.51) | HINT1NT5EHPGDSTING1GSK3A | |
| SCHEMBL16471919 | 0.75 | HINT1 (0.51) | HINT1NT5EHPGDSTING1GSK3A | |
| SCHEMBL25813664 | 0.75 | HINT1 (0.51) | HINT1NT5EHPGDSTING1GSK3A | |
| SCHEMBL22577507 | 0.75 | HINT1 (0.51) | HINT1NT5EHPGDSTING1GSK3A | |
| SCHEMBL1582222 | 0.74 | STING1 (0.41) | HINT1NT5EHPGDSTING1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | HINT1 1707/4885NT5E 337/4885HPGD 4231/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | HINT1 1707/4885NT5E 337/4885HPGD 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.